INTRODUCTION
Alzheimer's disease leads to cognitive impairment and is eventually fatal. The cognitive decline is associated with extensive neuronal degeneration. The most well known pathological features of Alzheimer's disease are extracellular b-amyloid plaques, intracellular tau tangles, neuroinflammation, and neuronal loss. Less discussed is that Alzheimer's disease is often associated with cerebrovascular abnormalities [1] . Recently, the vasculature of 835 Alzheimer's disease postmortem samples were analyzed, and the conclusion was 'concurrent vascular disease strongly correlates with cognitive dysfunction' in Alzheimer's disease [2 & ]. The symptoms of Alzheimer's disease and cerebrovascular disease could be independent comorbidities, with both being increased in aging populations. However, it is also possible that there is a mechanistic link between Alzheimer's disease and vascular disease.
IF ALZHEIMER'S DISEASE AND VASCULAR DISEASE ARE CONNECTED, WHAT ARE THE MECHANISTIC LINKS?
Although the mechanisms behind neuronal dysfunction and cognitive decline in Alzheimer's disease are heterogeneous and complex, abundant evidence points to accumulation of b-amyloid as one cause of Alzheimer's disease. b-Amyloid is generated when amyloid-b precursor protein (APP) is cleaved by b and g-secretases. Although the primary physiological function of APP is still unclear, it can participate in neurogenesis, synapse formation, and cell adhesion [3, 4] . Once liberated from APP on the cell surface, b-amyloid is released into the extracellular space and can form aggregation-prone oligomers, protofibrils, and fibrils in the brain parenchyma. Normally, the generation of b-amyloid in the brain is balanced by its clearance, and its accumulation in Alzheimer's disease is thought to be the result of
A POSSIBLE ROLE OF b-AMYLOID FIBRINOGEN INTERACTION IN ALZHEIMER'S DISEASE
Alzheimer's disease patients show increased fibrin deposition in the brain, including areas associated with cell death [9] [10] [11] [12] [13] , suggesting that fibrin accumulation may contribute to neurodegeneration in Alzheimer's disease. This idea is supported by work in Alzheimer's disease mice. Similar to Alzheimer's disease patients, Alzheimer's disease mice have increased fibrin deposition in their brains, with fibrin colocalizing with dystrophic neurites [9, 10, 14 & ]. Pharmacological or genetic reduction of circulating fibrinogen in Alzheimer's disease mice reduces fibrin deposition in the brain and improves their cognitive performance [10] , indicating that fibrin deposition participates in the development and/or progression of Alzheimer's disease in this model. Furthermore, fibrinogen-derived peptides are also increased in the plasma and CSF of Alzheimer's disease patients [15] [16] [17] , indicating that fibrinogen or fibrinogen-derived peptides could be potential biomarkers for diagnosis in some Alzheimer's disease patients.
The inflammatory properties of fibrin together with its potential role in CNS signal transduction provide a possible mechanistic link between fibrin deposition in the brain, neuroinflammation, and neuronal dysfunction [18, 19] . In addition to its pathological effects in the brain parenchyma, persistent fibrin within blood vessel walls and in the vessel lumen can also contribute to Alzheimer's disease. Fibrin clots can occlude capillaries and restrict blood flow, leading to microinfarcts and damage to downstream cells.
In Alzheimer's disease, fibrin(ogen) deposition may be precipitated and/or exacerbated by its interaction with b-amyloid [20] [21] [22] , which has been investigated using electron microscopy, X-ray crystallography, and other in-vitro techniques. b-amyloid specifically interacts with fibrinogen with a K d of 26.3 AE 6.7 nmol/l and also binds to preformed fibrin fibrils [20, 21] . b-amyloid-fibrin(ogen) binding is mediated by the central region of b-amyloid and by two regions on fibrin(ogen), the C-terminus of the b-chain and the a C region of the a-chain [20] [21] [22] . Binding of b-amyloid to fibrinogen has functional consequences: it induces a structural change in the C-terminal region of the fibrinogen b-chain (b384-393) [22] , precipitates fibrinogen oligomerization [20] , and results in the formation of fibrin with increased resistance to fibrinolysis [10, 21] . b-amyloid delays fibrinolysis via two mechanisms: by inducing a tighter fibrin network composed of thinner fibers; and by inhibiting the plasmin(ogen)-fibrin interaction [21] , likely through steric interference with plasminogen's binding sites on fibrin Aa residues 148-160 and on the aC region of fibrin, which are in close spatial proximity to the b-chain and aC binding sites of b-amyloid, respectively. Another consequence of b-amyloid binding to the aC region of fibrinogen and blocking plasmin-mediated cleavage at this site is the generation of increased levels of a plasminresistant fibrin degradation fragment [22] , which if found in Alzheimer's disease patients, could serve as a possible marker of fibrin(ogen)-related Alzheimer's disease.
In the brain parenchyma, extravasated fibrin(ogen) could come in contact with high concentrations of soluble b-amyloid released from neurons and with soluble b-amyloid surrounding b-amyloid plaques. In the vessel wall, fibrinogen may interact with increased levels of soluble b-amyloid near cerebral amyloid angiopathy deposits [23, 24] . Thus, the interaction between b-amyloid and fibrinogen in the brain parenchyma and/or vessels may result in the formation of abnormal, persistent fibrin and in its deposition along cerebrovascular walls. Over time, this could lead to microinfarcts with subsequent hemorrhage, inflammation, and blood-brain barrier disruption, all pathologies commonly observed in Alzheimer's disease.
KEY POINTS
b-amyloid can interact with fibrinogen leading to structurally abnormal, persistent blood clots.
b-amyloid can interact with factor XII leading to increased clotting and release of the proinflammatory peptide bradykinin.
The interaction of b-amyloid with fibrinogen and/or factor XII could participate in Alzheimer's disease pathophysiology.
b-amyloid has been shown to interact with numerous other circulating components, including erythrocytes [25, 26] , tissue plasminogen activator [27] , apolipoprotein E [28] , apolipoprotein J [29] , a2-macroglobulin [30] , albumin [31] , and members of the classical and alternative complement cascades [32, 33] . These interactions between b-amyloid and mediators of coagulation and inflammation could predispose blood to clotting. Indeed, there is evidence that circulating b-amyloid can elicit a clinically meaningful prothrombotic state, as plasma b-amyloid levels are correlated with infarctions as determined by MRI [34] . This prothrombotic state might be manifest in areas most sensitive to circulatory deficits, such as the hippocampus [35] , providing one mechanism by which circulating b-amyloid could contribute to initiation of neurodegeneration in that region. At the same time, these interactions could contribute to the development of a systemic proinflammatory state. The idea that peripheral inflammation may contribute to neuropathology in Alzheimer's disease is supported by studies demonstrating that peripheral markers of inflammation increase the risk of Alzheimer's disease, that incidence of systemic infections increase the risk of dementia, and that cognitive impairment in Alzheimer's disease is exacerbated during and after systemic infection [36] [37] [38] . Thus, activation and/or modulation of the delicately balanced coagulation and inflammatory systems by b-amyloid could lead to minor but chronic and pathological occlusion and inflammation, both of which could contribute to the neuronal death observed in Alzheimer's disease.
THE FACTOR XII CONTACT SYSTEM IS SIGNIFICANT IN ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN HUMANS AND MOUSE MODELS
b-amyloid also binds to and activates coagulation factor XII, which can then initiate the contact system [39] [40] [41] [42] [43] , a proteolytic cascade that leads both to clot formation through the intrinsic coagulation pathway and also to inflammation via bradykinin release after high-molecular weight kininogen cleavage. b-amyloid-mediated activation of factor XII could be one mechanism behind the increased contact system activation observed in the plasma and CSF of Alzheimer's disease patients and mouse models [39, 40] The contact system can initiate vascular disease and inflammation, both of which are implicated in Alzheimer's disease. Thus, this system could contribute to these pathologies in Alzheimer's disease.
Connections between factor XII and Alzheimer's disease have been reported: b-amyloid plaques contain factor XII [44] , the Alzheimer's disease brain parenchyma exhibits higher plasma kallikrein (PK) activity [45 & ], and Alzheimer's disease patients have increased high-molecular weight kininogen cleavage in their CSF [46] . In addition, Alzheimer's disease patients and mice have higher plasma levels of activated factor XIIa and increased high-molecular weight kininogen cleavage compared with controls [39] .
To determine if factor XII is causally related to Alzheimer's disease, plasma factor XII was depleted in Alzheimer's disease mice using antisense oligonucleotide-mediated mRNA knockdown. This depletion inhibited high-molecular weight kininogen cleavage in plasma and reduced neuroinflammation, fibrin(ogen) deposition, and neuronal degeneration in the brain. The improved brain disease was accompanied by better cognitive function [47] . These results provide a mechanistic link between b-amyloid and the contact system with resulting neuroinflammation, neuronal degeneration, and cognitive impairment.
There is no effective treatment for Alzheimer's disease. However, a link between factor XII activation and the pathogenesis of Alzheimer's disease provides a possible novel approach to treatment. The contact system is an attractive target for therapy [48] . Humans deficient in factor XII and mice with knockout of the factor XII, factorXI, or high-molecular weight kininogen gene all have normal hemostasis. Deficiencies in the contact system protect mice from thrombogenic challenges such as clotting after arterial injury and experimental cerebral ischemia [49, 50] .
As preventing factor XII activation attenuates Alzheimer's disease in a mouse model [47] , therapies designed to block the contact system might slow disease progression while not affecting normal hemostasis. In addition, this approach would block bradykinin release from high-molecular weight kininogen and thereby reduce inflammation in this disease. Thus, the contact system might represent new targets to suppress both thrombotic and inflammatory contributions to Alzheimer's disease progression. Positive results might be able to be applied to Alzheimer's disease patients rapidly. For example, a small molecule inhibitor of PK, ecallantide, is currently approved for treatment of hereditary angioedema [51] . An antibody inhibitor of PK [52] has also been developed, which is slated for a phase 3 trial and possible Food and Drug Administration approval by 2018. Some of these reagents might be useful for the treatment of Alzheimer's disease in the future. 
CONCLUSION
The data reviewed here suggest that the interaction of b-amyloid with fibrin(ogen) can lead to increased fibrin deposition in cerebral blood vessels, and that these accumulated fibrin deposits may disrupt cerebral blood flow and induce microinfarcts, inflammation, and blood-brain barrier damage, all of which are aspects of cerebrovascular dysfunction observed in Alzheimer's disease. At the same time, b-amyloid's ability to activate factor XII may contribute to increased fibrin generation through the intrinsic coagulation pathway as well as to increased inflammation and vascular permeability through bradykinin release from high-molecular weight kininogen. These possible roles of b-amyloid in thrombosis, fibrinolysis, and inflammation via its interaction with fibrinogen and factor XII are summarized in Fig. 1 .
Combination therapy has been indispensable in making therapeutic breakthroughs in other complex diseases like cancer and AIDS. Alzheimer's disease is an extremely complex disease with many probable pathogenic mechanisms, and treatment will likely involve combination therapy targeting various aspects of the pathological network [53] . The interactions of b-amyloid with fibrinogen and factor XII described here are possible components of this network. If these mechanisms are involved in Alzheimer's disease pathophysiology, targeted therapy could be designed for Alzheimer's disease patients identified as having circulatory abnormalities stemming from b-amyloid's interaction with these blood components. Given the heterogeneity of this disease, targeting a combination of different pathogenic pathways in different individuals will likely be a valuable approach to treatment.
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